title: The impact of intra-articular methylprednisolone acetate injection on fructosamine levels in diabetic patients with osteoarthritis of the knee, a case-control study.
abstract: Fructosamine is a glycated protein that reflects blood glucose control over the last 2-3 weeks. There are no studies that address the impact of intra-articular injection (IAI) of methylprednisolone acetate (MPA) on fructosamine levels among patients with type-2 diabetes and osteoarthritis of the knee (OAK). Non-selected patients attending the rheumatology or orthopedic clinic with type-2 diabetes and painful OAK, who failed non-steroidal anti-inflammatory drugs (NSAIDS) and physical therapy, were asked to participate in our study. After consent blood tests were drown for fructosamine, hemoglobin A1c (HbA1c) level, complete blood count, lipid profile, serum albumin, serum protein, c-reactive protein, and erythrocyte sedimentation rate. Demographic and different clinical parameters were also documented. Immediately after that, patients had IAI of 80 mg of MPA at the knee joint (group 1). Two to three weeks later, the same blood tests were repeated (except for HbA1c). Age- and sex-matched group of patients with type-2 diabetes and painful OAK attending the same clinics, but who were managed by NSAIDS were asked to participate as a control group (group 2) and had the same evaluation at enrollment and 2-3 weeks later, after consent. Eighteen patients from either group completed the study. Mean fructosamine level in group 1 patients was 263.7 ± 31.8 mg% prior to the IAI vs. 274.6 ± 39.3 mg% (p = 0.035), 2-3 weeks later, while mean fructosamine level in the control group (group 2) at enrollments was 274.2 ± 31.2 mg% vs. 269 ± 30.2 mg%, p = 0.509, 2-3 weeks later. There was no significant change in any other parameter tested at enrollment in either group, compared to those obtained 2-3 weeks afterwards. Body mass index was on the edge of significance as a predictor for a significant change in fructosamine level in group 1 patients. IAI of 80 mg of MPA in patients with type-2 diabetes and OAK had resulted in a significant, though mild increase in fructosamine levels 2-3 weeks later.
authors.affiliation: Rheumatology Unit, Laniado Medical Center, Netanya, Israel. gshabib62@yahoo.com.|Faculty of Medicine, Technion, Haifa, Israel. gshabib62@yahoo.com.|Rheumatology Clinic, Nazareth Hospital, Nazareth, Israel. gshabib62@yahoo.com.
authors.forename: George
authors.initials: G
authors.lastname: Habib
authors.affiliation: Department of Pediatrics, Rambam Medical Center, Haifa, Israel.
authors.forename: Fahed
authors.initials: F
authors.lastname: Sakas
authors.affiliation: Department of Radiology, Nazareth hospital, Nazareth, Gallile faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel.
authors.forename: Suheil
authors.initials: S
authors.lastname: Artul
authors.affiliation: Department of Orthopedics, Carmel Medical Center, Haifa, Israel.
authors.forename: Fadi
authors.initials: F
authors.lastname: Khazin
authors.affiliation: Department of Orthopedics, Nazareth Hospital, Nazareth, Israel.
authors.forename: Geries
authors.initials: G
authors.lastname: Hakim
authors.affiliation: Central lab, Nazareth hospital, Nazareth, Israel.
authors.forename: Adel
authors.initials: A
authors.lastname: Jabbour
authors.affiliation: Ophthalmology Unit, Poryia Medical Center, Gallile Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel.
authors.forename: Haneen
authors.initials: H
authors.lastname: Jabaly-Habib
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D019270:Fructosamine / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007270:Injections, Intra-Articular; D007557:Israel; D016014:Linear Models; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D008875:Middle Aged; D015999:Multivariate Analysis; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D026741:Physical Therapy Modalities; D017211:Treatment Failure
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D002097:C-Reactive Protein; D019270:Fructosamine; D006442:Glycated Hemoglobin; D008775:Methylprednisolone; D000077555:Methylprednisolone Acetate
keywords: Fructosamine; Intra-articular corticosteroid injection; Methylprednisolone acetate; Osteoarthritis of the knee; Type-2 diabetes